Thrombosis Research
Volume 118, Issue 4 , Pages 455-461 , 2006

Endothelial function is impaired in patients with primary antiphospholipid syndrome

  • Monika Štalc

      Affiliations

    • Department of Vascular Disease, Zaloška c.7, Clinical Centre, SI-1000 Ljubljana, Slovenia
    • Corresponding Author InformationCorresponding author. Tel.: +386 1 522 80 32; fax: +386 1 522 80 70.
    • ,
  • Pavel Poredoš

      Affiliations

    • Department of Vascular Disease, Zaloška c.7, Clinical Centre, SI-1000 Ljubljana, Slovenia
    • ,
  • Polona Peternel

      Affiliations

    • Department of Vascular Disease, Zaloška c.7, Clinical Centre, SI-1000 Ljubljana, Slovenia
    • ,
  • Matija Tomšič

      Affiliations

    • Department of Rheumatology, Clinical Centre, Ljubljana, Slovenia
    • ,
  • Miran Šebeštjen

      Affiliations

    • Department of Vascular Disease, Zaloška c.7, Clinical Centre, SI-1000 Ljubljana, Slovenia
    • ,
  • Tanja Kveder

      Affiliations

    • Department of Rheumatology, Clinical Centre, Ljubljana, Slovenia

Received 30 June 2005 ,Revised 8 September 2005 ,Accepted 12 September 2005.

References 

  1. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309–1311
  2. Riboldi P, Gerosa M, Raschi E, Testoni C, Meroni PL. Endothelium as a target for antiphospholipid antibodies. Immunobiology. 2003;207:29–36
  3. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation. 1999;99:1997–2002
  4. Amengual O, Atsumi T, Khamashta MA. Tissue factor in antiphospholipid syndrome: shifting the focus from coagulation to endothelium. Rheumatology (Oxford). 2003;42:1029–1031
  5. Poredoš P. Endothelial dysfunction in the pathogenesis of atherosclerosis. Clin Appl Thromb Hemost. 2001;7:276–280
  6. Vogel RA. Measurement of endothelial function by brachial artery flow-mediated vasodilation. Am J Cardiol. 2001;88:31E–34E
  7. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111–1115
  8. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation. 2003;108:2054–2059
  9. Celermajer DS. Endothelial dysfunction: does it matter? Is it reversible?. J Am Coll Cardiol. 1997;30:325–333
  10. Kaplanski G, Cacoub P, Farnarier C, Marin V, Gregoire R, Gatel A, et al. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum. 2000;43:55–64
  11. Combes V, Simmon AC, Grau GE. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest. 1999;104:93–102
  12. Dignat-George F, Camoin-Jau L, Sabatier F, Arnoux D, Anfosso F, Bardin N, et al. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost. 2004;91:667–673
  13. Atsumi T, Khamashta MA, Haworth RS, Brooks G, Amengual O, Ichikawa K, et al. Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1. Arthritis Rheum. 1998;41:800–807
  14. Forastiero RR, Martinuzzo ME, de Larranaga GF. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus. 2005;14:129–136
  15. Williams FM, Parmar K, Hughes GR, Hunt BJ. Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb Haemost. 2000;84:742–746
  16. Mercanoglu F, Erdogan D, Oflaz H, Kucukkaya R, Selcukbiricik F, Gul A, et al. Impaired brachial endothelial function in patients with primary anti-phospholipid syndrome. Int J Clin Pract. 2004;58:1003–1007
  17. Meroni PL, Borghi MO, Raschi E, Ventura D, Sarzi Puttini PC, Atzeni F, et al. Inflammatory response and the endothelium. Thromb Res. 2004;114:329–334
  18. Yasuda S, Atsumi T, Ieko M, Koike T. Beta2-glycoprotein I, anti-beta2-glycoprotein I, and fibrinolysis. Thromb Res. 2004;114:461–465
  19. Eidelman RS, Hennekens CH. Fibrinogen: a predictor of stroke and marker of atherosclerosis. Eur Heart J. 2003;24:499–500
  20. de Pablo P, Ramirez A, Cortina E, de la Pena A, Zamora J, Izaguirre R, et al. Increased fibrin polymerization rate in patients with primary antiphospholipid syndrome and systemic lupus erythematosus. Clin Appl Thromb Hemost. 2003;9:221–225
  21. Stegnar M, Vene N, Bozic M. Do haemostasis activation markers that predict cardiovascular disease exist?. Pathophysiol Haemost Thromb. 2003;33:302–308
  22. Vene N, Mavri A, Kosmelj K, Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost. 2003;90:1163–1172
  23. Medina G, Casaos D, Jara LJ, Vera-Lastra O, Fuentes M, Barile L, et al. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis. 2003;62:607–610
  24. Ames PR, Margarita A, Sokoll KB, Weston M, Brancaccio V. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis. 2005;64:315–317
  25. Baron MA, Khamashta MA, Hughes GR, D'Cruz DP. Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis. 2005;64:144–146
  26. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor improves endothelial function within 1 month. Circulation. 1997;95:1126–1131
  27. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 1994;89:2519–2524
  28. Sebestjen M, Zegura B, Keber I. Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia. J Intern Med. 2002;251:77–85
  29. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation. 1996;94:258–265
  30. Meroni PL, Raschi E, Testoni C. Endothelium as a target for anti-phospholipid antibodies and for therapeutical intervention. Autoimmun Rev. 2002;1:55–60
  31. Meroni PL, Raschi E, Testoni C, Tincani A, Balestrieri G, Molteni R, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 2001;44:2870–2878
  32. Ferrara DE, Swerlick R, Casper K, Meroni PL, Vega-Ostertag ME, Harris EN, et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost. 2004;2:1558–1563
  33. Meroni PL, Luzzana C, Ventura D. Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases?. Clin Rev Allergy Immunol. 2002;23:263–277

PII: S0049-3848(05)00383-X

doi: 10.1016/j.thromres.2005.09.005

Thrombosis Research
Volume 118, Issue 4 , Pages 455-461 , 2006

Article Tools

* Image Usage & Resolution